Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Pooled Post Hoc Analyses Through 1 Year of Two Phase 3 Studies

被引：0

作者：

Coates, Laura C. ^{[1
]}

Ramirez, Julio ^{[2
]}

McGonagle, Dennis ^{[3
]}

Aydin, Sibel ^{[4
]}

Zimmermann, Miriam ^{[5
]}

Nantel, Francois ^{[6
]}

Shawi, May ^{[7
]}

Rampakakis, Emmanouil ^{[8
,9
]}

Nash, Peter ^{[10
,11
]}

Mease, Philip ^{[12
,13
]}

机构：

[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford, England

[2] Hosp Clin Barcelona, Dept Rheumatol, Arthrit Unit, Barcelona, Spain

[3] Univ Leeds, Leeds Biomed Res Ctr, Leeds, England

[4] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada

[5] Janssen Sci Affairs LLC, Immunol, Zug, Switzerland

[6] Nantel Medsci Consult, Montreal, PQ, Canada

[7] Janssen Pharmaceut Co Johnson Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA

[8] McGill Univ, Dept Pediat, Montreal, PQ, Canada

[9] JSS Med Res, Montreal, PQ, Canada

[10] Griffith Univ, Maroochydore, Australia

[11] Univ Queensland, Maroochydore, Australia

[12] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[13] Univ Washington, Seattle, WA USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB152 / AB152

页数：1

共 50 条

[21] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana-Maria Bravo
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4175 - 4178
[22] Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
Arthur Kavanaugh
Dafna D. Gladman
Christopher J. Edwards
Georg Schett
Benoit Guerette
Nikolay Delev
Lichen Teng
Maria Paris
Philip J. Mease
Arthritis Research & Therapy, 21
[23] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 79 - 79
[24] Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies
McInnes, Iain B.
Ritchlin, Christopher T.
Rahman, Proton
Puig Sanz, Lluis
Gottlieb, Alice B.
Li, Shu
Song, Michael
Randazzo, Bruce
Wang, Yuhua
Mendelsohn, Alan M.
Kavanaugh, Arthur
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S685 - S686
[25] Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Mease, Philip
Fleischmann, Roy
Davies, Owen
Nurminen, Tommi
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S685 - S685
[26] DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICT LONG-TERM OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
Mease, P. J.
Fleischmann, R.
Davies, O.
Nurminen, T.
van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 741 - 741
[27] Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-na_ive Patients With Psoriatic Arthritis (PsA)
Gladman, Dafna D.
Starr, Michael
Ranza, Roberto
Bravo, Ana-Maria
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip J.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB189 - AB189
[28] SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
Ritchlin, C. T.
Mease, P. J.
Boehncke, W. H.
Tesser, J.
Schiopu, E.
Chakravarty, S. D.
Kollmeier, A.
Hsia, E. C.
Xu, X. L.
Shawi, M.
Jiang, Y.
Sheng, S.
Merola, J. F.
McInnes, I.
Deodhar, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1291 - 1292
[29] Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies
McGonagle, Dennis
McInnes, Iain
Deodhar, Atul
Schett, Georg
Mease, Philip
Shawi, May
Kafka, Shelly
Karyekar, Chetan
Kollmeier, Alexa
Hsia, Elizabeth
Xu, Xie
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Ritchlin, Christopher
Rahman, Proton
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[30] EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES
Mcgonagle, D.
Mcinnes, I.
Deodhar, A.
Schett, G.
Mease, P. J.
Shawi, M.
Kafka, S.
Karyekar, C.
Kollmeier, A.
Hsia, E. C.
Xu, X. L.
Sheng, S.
Agarwal, P.
Zhou, B.
Ritchlin, C. T.
Rahman, P.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1697 - 1697

← 1 2 3 4 5 →